Potassium channel blocker
Fampridine
Brand names: Fampyra
Adult dose
Dose: 10mg BD (12h apart) on empty stomach
Route: PO
Frequency: BD
Clinical pearls
- Walking difficulty in adults with MS; 4-week trial — discontinue if no benefit
- Specialist MS prescribing
Contraindications
- History of seizures
- Renal impairment (CrCl ≤80 mL/min)
- Concurrent OCT2 inhibitors (cimetidine)
Side effects
- Seizures (dose-dependent)
- UTI
- Insomnia
- Dizziness
- Headache
Interactions
- Cimetidine (OCT2 inhibitor — avoid)
- Other lower-seizure-threshold drugs
Monitoring
- Walking improvement (e.g. T25FW)
- U&E
Reference: BNF; NICE TA833; SmPC; https://bnf.nice.org.uk/drugs/fampridine/. Verify against your local formulary and the latest BNF before prescribing.
Related
Curated clinical cross-links plus same-class fallbacks.
Calculators
- MAGGIC Heart Failure Risk Score · Heart Failure
- Long QT Syndrome (Schwartz Score) · Channelopathy / Sudden Cardiac Death
- Hyperkalaemia Management Algorithm · Electrolyte Disorders
- Transtubular Potassium Gradient (TTKG) · Electrolytes
- Potassium Deficit Calculator · Electrolytes
- Hyperkalaemia Severity and ECG Risk · Electrolytes
Pathways
- Acute Stroke / TIA Assessment · NICE NG128; RCP Stroke Guidelines 2023
- Status Epilepticus (Adults) · NICE CG137; ESEM guidelines; RCP Neurology Guidelines
- Acute Stroke Management · NICE NG128 / RCP 2023
- TIA Assessment (ABCD2) · NICE NG128 / NICE CG68
- Bacterial Meningitis (Adults) · NICE CG102 / BIA 2016
- Parkinson's Disease Management · NICE NG71 2017